nephrology

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

NHS trust rolls out digital health tool for kidney disease

An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

Unicycive eyes June FDA verdict for hyperphosphataemia drug

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis, which hopes to improve on 'onerous' phos

News

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t

Vertex preps FDA filing for IgAN drug after phase 3 readout

Novo builds pipeline again with $2.1bn Omeros deal

NHS trust rolls out digital health tool for kidney disease

Otsuka, Vera stake their claims to IgAN treatment

Unicycive eyes June FDA verdict for hyperphosphataemia drug

Biogen shows its IgAN hand with felzartamab data

Regenxbio, Solid report data with Duchenne gene therapies

Using AI-driven synthetic personas to take your insights fur...

nephrology

Editor's Picks